HIV PEP after possible exposure in Dubai, Abu Dhabi, Sharjah and the UAE
HIV post-exposure prophylaxis (PEP) is a 28-day course of antiretroviral medicines prescribed after a potentially significant HIV exposure. It must be assessed urgently and, when indicated, started as soon as possible—ideally within 24 hours and no later than 72 hours after exposure. The first dose should not be postponed while waiting for routine laboratory results. PEP reduces the chance of acquiring HIV but cannot guarantee prevention and does not treat other sexually transmitted infections.
STDtest.clinic offers a clinician-guided pathway for exposure assessment, HIV and STI testing, prescription evaluation, eligible medication dispensing and follow-up. Where authorized, clinically appropriate and operationally available, assessment and selected services can be arranged at home or at a hotel. If a home visit would delay the first PEP dose, seek an emergency-capable medical service immediately.
The first 72 hours determine the immediate plan
Within 24 hours: Seek assessment immediately. Starting indicated PEP earlier is preferable; there is no reason to wait for symptoms, a partner’s laboratory report or the next convenient appointment.
Between 24 and 72 hours: PEP may still be indicated. Contact an urgent-care or emergency-capable clinician now. A negative HIV test taken immediately after the incident cannot exclude HIV acquired during that exposure.
After 72 hours: PEP is generally not recommended for that exposure under CDC guidance. Medical assessment still matters for baseline and repeat HIV testing, hepatitis B vaccination or other post-exposure care, STI evaluation, and PrEP planning for future prevention. Do not self-start leftover PEP tablets.
PEP is assessed based on exposure risk, not anxiety or symptoms alone. HIV does not cause immediately diagnostic symptoms, and many exposures do not require PEP. The decision considers the source’s known HIV status and viral load, exposure route, body fluid, mucosal or broken-skin contact, barrier use, PrEP adherence and elapsed time.
Exposures that may require HIV PEP
Condom breakage or slippage during vaginal or anal sex can warrant assessment when the partner has HIV without sustained viral suppression or their status is unknown and the exposure may present substantial risk. The risk is not identical for all sexual activities; receptive anal exposure generally carries higher HIV transmission risk than many other sexual exposures.
Sex without a condom may merit PEP evaluation after a potentially substantial exposure. Ejaculation, genital trauma, bleeding, concurrent STIs and other factors can inform the clinical assessment, but their absence does not automatically eliminate risk.
Oral sex alone usually carries little to no HIV transmission risk and does not routinely justify PEP, although blood exposure, significant mucosal injury or other unusual circumstances warrant individual assessment. Oral sex can still transmit gonorrhea, syphilis, herpes and other STIs.
Sharing needles, syringes or injection equipment can create blood-borne HIV exposure. Urgent assessment should also consider hepatitis B and hepatitis C, wound care and safer-injection support.
Needlestick or blood splash exposure needs assessment of whether infectious blood reached a percutaneous injury, mucous membrane or non-intact skin. Workplace occupational exposures follow a dedicated protocol and should be reported immediately through the employer’s occupational-health pathway.
Sexual assault requires urgent, trauma-informed care. In addition to HIV PEP evaluation, a person may need forensic options, injury assessment, emergency contraception, STI prophylaxis, hepatitis B prevention and psychological support. The patient’s safety and preferences guide care.
Contact with intact skin, casual touching, sharing utensils, hugging, mosquito bites, saliva without blood and ordinary household contact do not transmit HIV. PEP is not indicated for these activities.
Sex with a partner living with HIV who has sustained viral suppression: People who maintain an undetectable HIV viral load through effective ART do not transmit HIV sexually (U=U). A clinician should review the reliability and recency of this information; PEP is not routinely indicated when sustained suppression is established.
PEP medicines, active ingredients and standard adult formulations
CDC’s 2025 preferred nonoccupational PEP regimens for most eligible adults and adolescents are three-drug combinations. They are chosen by a qualified prescriber according to HIV testing, renal and liver function, pregnancy, prior antiretroviral exposure, hepatitis B, allergies, resistance concerns, other medicines and local availability. The examples below are medical information, not instructions to self-prescribe.
Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a preferred single-tablet option. The branded product Biktarvy contains bictegravir 50 mg, emtricitabine 200 mg and tenofovir alafenamide 25 mg per tablet; the usual adult formulation is taken once daily when prescribed. Although this combination is also used to treat HIV, its use as PEP is a distinct clinician-directed indication in CDC 2025 guidance.
Dolutegravir (DTG) plus two nucleoside/nucleotide agents is another preferred strategy: DTG with either TAF or TDF, together with FTC or lamivudine (3TC). A common adult formulation is dolutegravir 50 mg once daily with TDF 300 mg/FTC 200 mg once daily, when clinically suitable. Tivicay (dolutegravir), Truvada (TDF/FTC) and certain generics are product examples, not promises of UAE stock. Other TAF-containing formulations may be selected according to the actual prescription and local product registration.
PEP should not be confused with two-drug oral PrEP. Taking TDF/FTC alone after a high-risk exposure is not equivalent to a standard three-drug PEP regimen. PrEP is preventive medication used before future exposures; confirmed HIV infection requires full HIV treatment rather than a PEP-only pathway.
The recommended duration is 28 consecutive days. A full course, or a starter supply with a guaranteed plan to obtain the remainder, should be arranged without interruption. If the pharmacy cannot supply a prescribed option, the clinician must select an appropriate alternative rather than leaving the patient to improvise doses.
Drug interactions matter. Antacids and supplements containing calcium, iron, magnesium or aluminium can interfere with integrase inhibitor absorption unless separated or taken according to product-specific instructions. Certain anticonvulsants, rifampicin and other medicines may require a different regimen. Share all prescribed drugs, over-the-counter products, supplements and previous PrEP/PEP medicines with the clinician.
What testing is needed before and after PEP?
Baseline testing should be collected promptly but should not delay the first indicated dose. Assessment commonly includes a rapid or laboratory HIV antigen/antibody test; serum creatinine for kidney function; liver enzymes ALT and AST; hepatitis B markers; and a pregnancy test when relevant. Hepatitis C, syphilis, gonorrhea and chlamydia testing depend on the exposure and anatomical sites. Recent long-acting injectable PrEP can make baseline HIV NAT particularly important.
A negative baseline HIV test does not rule out HIV acquired from the incident that just occurred. It is used mainly to assess whether infection was already detectable before starting PEP. If an initial HIV result is reactive or HIV is diagnosed during PEP, the clinician must arrange confirmatory testing and rapid specialist HIV treatment evaluation; do not stop antiretrovirals independently.
Early follow-up should occur within about 24 hours of starting PEP. This confirms that medication was obtained, the first doses were tolerated, no interactions were missed and the patient understands the 28-day schedule.
CDC 2025 recommends follow-up HIV testing with a laboratory antigen/antibody test and diagnostic HIV NAT at approximately 4–6 weeks and 12 weeks after exposure. The 4–6-week visit may be deferred in selected people who started within 24 hours and completed every dose, as assessed by the clinician. Final follow-up is important because antiretroviral use can delay detectable markers of infection. Local protocols and the individual’s circumstances determine the exact appointments.
Kidney and liver tests are not necessarily repeated at every visit. Repeat biochemistry is usually targeted to abnormal baseline results, symptoms or other clinical concerns. Follow-up for hepatitis and other STIs is tailored to the specific exposure.
How effective is PEP and what can reduce its protection?
PEP is highly effective when taken correctly, but no honest clinic can promise 100% protection. Effectiveness depends on how soon medication starts, whether the regimen is appropriate, completing all 28 days, avoiding significant interactions and whether additional exposures occur during follow-up.
Missing a dose does not mean PEP has automatically failed. Take the missed dose when remembered unless it is nearly time for the next dose, and follow the specific product and clinician instructions; do not double up to compensate. Contact the prescriber promptly after repeated missed doses, vomiting soon after a dose or difficulty obtaining tablets.
Side effects are often manageable. Nausea, loose stools, headache and fatigue may occur. Persistent vomiting, a widespread rash, jaundice, severe abdominal pain or other serious symptoms require prompt medical advice. A clinician can evaluate side effects and change the regimen if necessary rather than leaving HIV prevention interrupted.
PEP does not make sex or needle sharing risk-free during the course. Use condoms and avoid sharing injection equipment. New exposures should be reported because they can affect counselling and the testing plan.
Special clinical situations
Pregnancy or breastfeeding: Potential pregnancy does not automatically rule out PEP. The clinician balances HIV acquisition risk, medication safety and maternal or infant considerations. Urgent assessment should not be postponed while seeking a routine pregnancy appointment.
Kidney disease: TDF and TAF differ in renal considerations. Kidney impairment may change the preferred regimen, so creatinine and estimated renal function are reviewed without delaying emergency initiation when PEP is indicated.
Hepatitis B: Tenofovir, emtricitabine and lamivudine also have hepatitis B activity. HBV status matters, particularly when these medicines are discontinued; patients with chronic HBV may need additional follow-up. A susceptible person may need hepatitis B vaccination and, after certain exposures, hepatitis B immune globulin.
Existing PrEP use: A patient who has taken oral PrEP consistently may not need PEP after every exposure. Missed doses, interrupted use, injectable PrEP schedules or possible acute HIV symptoms require individualized evaluation. Do not assume that taking a few PrEP tablets after sex is an adequate PEP course.
The source later tests HIV-negative: A reliable negative result can lead the clinician to discontinue PEP, after considering the source’s recent exposure history and possibility of acute infection. A patient should not independently stop prescribed treatment based on an unverified message or screenshot.
Exposure more than 72 hours ago: PEP is generally not started, but a negative test taken at that moment is not necessarily definitive. Plan appropriate follow-up HIV testing, STI screening and hepatitis prevention with a clinician.
Home and hotel PEP assessment, medicine supply and follow-up
A clinician can assess a possible HIV exposure at home or in a hotel when the visit is authorized, clinically appropriate and fast enough to protect the PEP start window. The appointment may include history-taking, HIV and STI test orders, suitable sample collection, medication reconciliation and prescription evaluation. Depending on verified licensing and pharmacy arrangements, eligible medication dispensing or delivery may be coordinated with the clinical service.
Time is more important than convenience. If immediate first-dose access cannot be assured through a mobile visit, STDtest.clinic should direct the patient to an emergency-capable service without delay. A home visit is not a substitute for emergency treatment of severe injury, major bleeding, sexual assault-related trauma or other acute medical needs.
The patient pathway is straightforward: urgent contact → exposure and timing assessment → first PEP dose when indicated → baseline tests without delaying treatment → complete 28-day medication access → early tolerability check → follow-up HIV testing → PrEP assessment where appropriate.
Dubai requests: STDtest.clinic’s stated primary location is Arjan. Subject to confirmed mobile-service coverage, enquiries may come from Dubai Marina, JBR, JLT, Palm Jumeirah, Downtown Dubai, Business Bay, DIFC, Jumeirah, Umm Suqeim, Dubai Hills Estate, Emirates Hills, Arabian Ranches, Al Barsha, City Walk, Bluewaters and Dubai Creek Harbour.
Abu Dhabi requests: Patients in Saadiyat Island, Al Maryah Island, Al Reem Island, Yas Island, Al Raha Beach, Khalifa City, Al Bateen and Corniche districts may enquire about an appropriate authorized pathway. Service in Abu Dhabi is not guaranteed solely by a Dubai license.
Sharjah and wider UAE: Requests from Al Majaz, Al Khan, Al Taawun, Muwaileh, Aljada and other UAE locations should be assessed against actual clinical coverage, emirate-specific permissions and ability to start medication immediately.
Privacy, costs and access to medication
Sexual-health consultations should be handled discreetly and professionally, with patient information protected according to applicable UAE healthcare requirements. Confidentiality should not be represented as anonymity or as an exemption from mandatory medical reporting. Patients should be told what information is collected, how results are communicated and any applicable disclosure obligations.
PEP cost depends on the prescribed regimen, clinical consultation, baseline investigations, medicine supply and follow-up testing. The clinic should quote an itemized price and clarify whether the full 28-day course is included. Avoid unverified claims that a named brand is always in stock, covered by insurance or available for immediate delivery.
STDtest.clinic reports DHA, MOHAP and medicine-sale permissions. Exact facility licensing, pharmacy dispensing rights, HIV prescribing scope and emirate-specific mobile permissions must be matched to the advertised service before the website promises at-home medication provision.
Preventing the next exposure: transition from PEP to PrEP
People who anticipate repeat HIV exposures can discuss PrEP before finishing PEP. After appropriate HIV assessment, a clinician may arrange an immediate transition from the 28-day PEP course to an eligible PrEP regimen without an unnecessary gap, with ongoing HIV testing because antiretroviral use can affect test interpretation.
PEP and PrEP do not prevent gonorrhea, chlamydia, syphilis, herpes or HPV. Depending on the exposure, site-specific STI screening, hepatitis B vaccination, HPV vaccination, condoms and partner testing may also be appropriate.
Arrange urgent PEP care in the UAE
If a possible HIV exposure occurred within the last 72 hours, seek immediate clinical assessment. Tell the team the approximate exposure time, type of contact, known source status, recent PrEP doses, other medications and any pregnancy or kidney concerns. The clinician can determine whether PEP is indicated and the fastest safe route to the first dose.
Request PEP Assessment | Contact a Clinician | HIV Testing Dubai | PrEP Dubai | Doctor at Home Dubai
Medical notice: This page provides general clinical information, not an individualized prescription. PEP medicines should not be started, shared, substituted or stopped without professional supervision. The service must not promise an on-demand home visit or immediate stock without confirming actual availability.